A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

Recruiting now

Conditions studied: Head and Neck Squamous Cell Carcinoma

In brief

The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.

Key facts

Study ID

NCT06163534

Run by

Tempus AI

People needed

500

Starts

2024-08-01

Expected to finish

2028-03-01

Last updated by the study team

2026-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥18 years of age
• Willing and able to provide informed consent
• Histologically- or cytologically-confirmed metastatic or unresectable, recurrent HNSCC unsuitable for local therapies
• Intended for first line anti-PD1 or PDL1 monotherapy or combination therapy
• Must submit tumor tissue sample representative of current disease per laboratory manual

You may not qualify if…

• Non-squamous histologies (eg, nasopharynx or salivary gland)
• Relapse or recurrence within 6 months of first line chemotherapy and / or chemoradiotherapy
• Tumors that are PD-L1 negative (CPS <1)
• Clinical evidence of an active second invasive malignancy within <2 years of enrollment with the exception of stable prostate cancer on watchful waiting, in situ cervical cancer, in situ breast carcinoma or localized non-melanoma skin cancers
• Unable to comply with study procedures (i.e., not willing or able to have additional blood samples collected)

Where it is running

• City of Hope — Duarte, California, United States (enrolling)
• USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)
• University of California, Los Angeles — Los Angeles, California, United States (enrolling)
• Stanford — Palo Alto, California, United States (enrolling)
• Providence Medical Foundation — Santa Rosa, California, United States (enrolling)
• Morehouse — Atlanta, Georgia, United States (enrolling)
• Piedmont Healthcare — Atlanta, Georgia, United States (enrolling)
• Winship Cancer Institute, Emory University — Atlanta, Georgia, United States (enrolling)
• Northwestern University Feinberg School of Medicine — Chicago, Illinois, United States (enrolling)
• Cancer Care Specialists of Illinois — Decatur, Illinois, United States (enrolling)
• Illinois Cancer Care — Peoria, Illinois, United States (enrolling)
• University of Kansas — Westwood, Kansas, United States (enrolling)
• University of Maryland — Baltimore, Maryland, United States (enrolling)
• Dana Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• Henry Ford — Detriot, Michigan, United States (enrolling)
• Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
• Oncology Hematology Associates — Springfield, Missouri, United States (enrolling)
• Washington University in St. Louis — St Louis, Missouri, United States (enrolling)
• Mount Sinai Hospital — New York, New York, United States (enrolling)
• Sanford Fargo — Fargo, North Dakota, United States (enrolling)
• University of Cincinnati — Cincinnati, Ohio, United States (enrolling)
• Cleveland Clinic — Cleveland, Ohio, United States (enrolling)
• Ohio State University — Columbus, Ohio, United States (enrolling)
• University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
• Cancer Care Associates of York — York, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.